1. What It Is (Mechanism of Action)

Tesamorelin is a synthetic 44-amino-acid peptide consisting of the complete human GHRH sequence attached to a trans-3-hexenoyl fatty acid moiety at the N-terminus, which confers enhanced enzymatic resistance to DPP-4 cleavage.

2. Clinical Indications Under Study

FDA-approved for the reduction of excess abdominal visceral adipose tissue in HIV-infected patients with lipodystrophy. Under active clinical investigation for MASH and non-alcoholic fatty liver disease.

3. FDA Approval & Regulatory Status

Status:FDA-Approved Prescription Drug (Egrifta)

FDA-Approved Prescription Drug (Egrifta)

4. Human Clinical Evidence Summary

In multicenter randomized Phase 3 trials, tesamorelin demonstrated sustained, statistically significant reductions in visceral adipose tissue (VAT) averaging 15–18% on MRI scans, alongside reductions in hepatic triglyceride content, without reducing beneficial subcutaneous fat.

5. Known Risks, Side Effects & Boxed Warnings

Arthralgia, peripheral edema, myalgia, injection site reactions, glucose intolerance (elevated fasting blood glucose and HbA1c), and hypersensitivity reactions. IGF-1 levels must be monitored periodically.

7. Why Gray-Market "Research Chemical" Versions Are Risky

Tesamorelin is one of the most fragile 44-amino-acid chains; unverified gray-market powders degrade rapidly, lose conformational potency, and carry high risk of immunogenic antibody formation.
Peptides Agora Intelligence Wire
Weekly Research Brief

Get Breaking Tesamorelin Clinical Trial Alerts

Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.

HPLC Purity Audits
Independent lab test readouts & endotoxin assays
FDA PCAC Advisory
503A / 503B compounding votes and legal dockets
Phase 2/3 Readouts
Incretin & repair peptide clinical trial data
Zero vendor sponsorship or commercial advertisingUnsubscribe anytime with one click

8. Questions to Ask a Licensed Clinician

If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:

  • Q1: What are the specific clinical criteria for prescribing FDA-approved tesamorelin?
  • Q2: How frequently should IGF-1 and fasting glucose levels be monitored during therapy?

9. Primary Peer-Reviewed Sources & Citations

  • [1] Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed / Source →
  • [2] U.S. FDA Approval Information: EGRIFTA (tesamorelin for injection). PubMed / Source →